There is one clinical trial.
COVID-19 is a respiratory disease caused by a novel coronavirus (SARS-CoV-2) and causes substantial morbidity and mortality. There is currently no vaccine to prevent Covid-19 or infection with SARS-CoV-2 or therapeutic agent to treat COVID-19. This protocol CORIMUNO19-COAG will evaluate the efficacy and safety of active anticoagulation using heparin: Tinzaparin (INNOHEP®) or unfractionated heparin (Calciparine®, Héparine Sodique Choay®) in COVID-19 patients hospitalized in conventional or intensive care units. It will use a phase 2 randomized open-label multicentre clinical trial, where patients will be randomly allocated to anticoagulation versus Standard of Care.
Description: group 1Measure: Survival without ventilation (VNI or mechanical ventilation) Time: day 14
Description: group 2Measure: ventilator free survival Time: day 28
Description: range from 0 (healthy) to 10 (death) values below or equal to 5 correspond to the absence of any oxygen supply beside nasal or facial maskMeasure: World Health Organisation(WHO) progression scale ≤5 Time: day 4
Description: range from 0 (healthy) to 10 (death)Measure: World Health Organisation(WHO) progression scale Time: day 4, 7 and 14
Description: according to Acute Kidney Injury (AKIN) classification systemMeasure: rate of acute kidney injury Time: day 28
Description: confirmed by objective testingMeasure: rate of clinically overt pulmonary embolism or proximal deep vein thrombosis Time: day 14 and day 90
Description: confirmed by objective testingMeasure: Rate of clinically overt arterial thrombosis Time: day 14 and day 90
Description: as a thrombus extending from the catheter into the lumen of the deep vein where the catheter is inserted diagnosed with radiologic imaging in case of a clinical suspicion of upper/lower limb DVT or pulmonary embolism or compulsory catheter removalMeasure: Rate of central venous catheter-related deep vein thrombosis (CVC-DVT) Time: day 28
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports